Get the full picture
Sign in to uncover key details.
Show More
Anthos Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
99 High St, Boston, Massachusetts, 02110...Website
www.anthostherapeutics.comRevenue
<$5 MillionIndustry
About Anthos Therapeutics
Anthos Therapeutics is focused on developing innovative anticoagulant therapies to address significant unmet medical needs, particularly in areas such as atrial fibrillation and cancer-associated thrombosis. The company is advancing its lead product, abelacimab, which is designed to provide effective anticoagulation with a reduced risk of bleeding. Their mission is to transform the lives of patients by improving treatment options for those at risk of thromboembolic events. Anthos Therapeutics aims to revolutionize anticoagulant therapy by targeting Factor XI, potentially changing the landscape of treatment for cardiovascular diseases.Explore more
Anthos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Anthos Therapeutics
Compare insights from companies similar to Anthos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Anthos Therapeutics Tech Stack
A closer look at the technologies used by Anthos Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anthos Therapeutics
Sign Up For FreeTo access detailed company insights
Anthos Therapeutics is focused on developing innovative anticoagulant therapies to address significant unmet medical needs, particularly in areas such as atrial fibrillation and cancer-associated thrombosis. The company is advancing its lead product, abelacimab, which is designed to provide effective anticoagulation with a reduced risk of bleeding.... Read More
